宫颈癌IMRT/VMAT联合4次近距离治疗与3DCRT联合5次近距离治疗的比较
本单中心回顾性研究纳入145例FIGO 2018 IB3–IVA期局部晚期宫颈癌患者,比较2008–2016年3DCRT+5次BT(n=77)与2017–2023年IMRT/VMAT+4次BT(n=68)两条治疗路径。中位随访60个月,PFS与OS差异无统计学意义,IMRT/VMAT组靶区覆盖更优、毒性更低、治疗完成更快。
要点
- IMRT/VMAT+4BT组PFS与OS数值上更优,但未达统计学显著性。
- IMRT/VMAT+4BT组49天内完成治疗比例63.2%,显著高于3DCRT+5BT组的20.8%。
核心结论
- 在这项基于年代的单中心两条治疗路径比较中,IMRT/VMAT+4BT取得数值上更好的肿瘤学结局但未达统计学显著性,同时靶区覆盖更优、毒性更低、治疗时间更短,但需考虑整体方案随时间变化的背景。
研究设计与样本
- 回顾性单中心研究,纳入2008–2023年治疗的145例FIGO 2018 IB3–IVA期局部晚期宫颈癌患者。
- 患者接受3DCRT+5次BT(2008–2016年,n=77)或IMRT/VMAT+4次BT(2017–2023年,n=68),均同步化疗。
主要发现
- 中位随访60个月,PFS无显著差异(HR 0.68,95%CI 0.34–1.38,p=0.285),OS亦无显著差异(HR 0.47,95%CI 0.17–1.29,p=0.133)。
- 组织学确认的残留肿瘤率IMRT/VMAT+4BT组为22.1%,3DCRT+5BT组为31.2%(p=0.262)。
- IMRT/VMAT+4BT组49天内完成治疗者占63.2%,3DCRT+5BT组为20.8%(p<0.001)。
- IMRT/VMAT组胃肠道、泌尿生殖、皮肤及黏膜毒性均显著更少(均p<0.05),全身状况恶化更少。
关键数值与推荐
- PFS:HR 0.68,95%CI 0.34–1.38,p=0.285。
- OS:HR 0.47,95%CI 0.17–1.29,p=0.133。
- 残留肿瘤率:22.1%(IMRT/VMAT+4BT)vs 31.2%(3DCRT+5BT),p=0.262。
- 49天内完成治疗比例:63.2% vs 20.8%,p<0.001。
临床怎么用
- 对于局部晚期宫颈癌,IMRT/VMAT联合4次BT可作为3DCRT联合5次BT的替代路径,有助于提高靶区剂量、缩短治疗时长并降低毒性。
- 采用该路径时仍应保证同步化疗,并按HRCTV D90及OAR D2cc进行剂量学评估与控制。
- 治疗时间缩短至49天内完成的比例更高,提示该路径可能有利于减少治疗相关时间延长的影响。
局限性
- 为回顾性、基于年代的单中心比较,两条路径与时间段混杂,无法排除时间趋势与其他同期治疗变化的影响。
- 样本量有限(145例),肿瘤学结局差异未达统计学显著性,需谨慎解读。
- 随访与终点为单中心资料,外推至其他机构需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Definitive radiochemotherapy with external beam radiotherapy and brachytherapy is standard for locally advanced cervical cancer (LACC). Advanced techniques like intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) have replaced 3D-conformal radiotherapy (3DCRT). This study compares two institutional definitive radiotherapy treatment pathways implemented in different time periods: 3DCRT with five BT fractions and IMRT/VMAT with four BT fractions. METHODS: This retrospective single-center study included 145 patients with FIGO 2018 stage IB3–IVA LACC treated during 2008–2023. Patients received 3DCRT+5BT (2008–2016; n = 77) or IMRT/VMAT+4BT (2017–2023; n = 68) with concurrent chemotherapy. Histopathological biopsies at final BT evaluated tumor response. Dosimetric parameters (HRCTV-D90–EQD2₍₁₀₎ and OAR-D2cc for bladder, rectum, sigmoid) were analyzed. Endpoints included treatment duration, residual tumor, progression-free survival (PFS), overall survival (OS), and toxicity. RESULTS: After a median follow-up of 60 months, no significant differences were seen in PFS (HR 0.68, 95% CI 0.34–1.38, p = 0.285) or OS (HR 0.47, 95% CI 0.17–1.29, p = 0.133). Histologically confirmed residual tumor rates were 22.1% (IMRT/VMAT+4BT) vs. 31.2% (3DCRT+5BT; p = 0.262). IMRT/VMAT+4BT patients more often completed therapy within 49 days (63.2% vs. 20.8%; p < 0.001). Median HRCTV D90 EQD2₍₁₀₎ was 85.3 Gy vs. 76.5 Gy (p < 0.001) in favor of IMRT/VMAT, while OAR doses remained within limits. IMRT/VMAT showed significantly fewer gastrointestinal, genitourinary, skin, and mucosal toxicities (all p < 0.05) and less systemic deterioration. CONCLUSION: In this era-based single-institution comparison of two treatment pathways, IMRT/VMAT+4BT achieved numerically better oncologic outcomes without reaching statistical significance. IMRT/VMAT+4BT showed improved target coverage, lower toxicity, and shorter treatment duration, within the context of an integrated regimen change over time.
引用
- Feroz B, Ebner C, Skvortsov S, et al. Intensity-modulated radiotherapy/Volumetric modulated Arc therapy including four Brachytherapy fractions versus 3D conformal radiotherapy containing five Brachytherapy fractions in the treatment of cervical cancer. Radiat Oncol. 2026. PMID: 41917961. doi:10.1186/s13014-026-02834-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。